Management of Postmenopausal Osteoporosis : ACOG Clinical Practice Guideline No. 2
Copyright © 2022 by the American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved..
PURPOSE: To provide updated evidence-based recommendations for the treatment of postmenopausal osteoporosis.
TARGET POPULATION: Postmenopausal patients with primary osteoporosis.
METHODS: This guideline was developed using an a priori protocol in conjunction with a writing team consisting of two specialists in obstetrics and gynecology appointed by the ACOG Committee on Clinical Practice Guidelines-Gynecology and one external subject matter expert. ACOG medical librarians completed a comprehensive literature search for primary literature within Cochrane Library, Cochrane Collaboration Registry of Controlled Trials, EMBASE, PubMed, and MEDLINE. Studies that moved forward to the full-text screening stage were assessed by two authors from the writing team based on standardized inclusion and exclusion criteria. Included studies underwent quality assessment, and a modified GRADE (Grading of Recommendations Assessment, Development, and Evaluation) evidence-to-decision framework was applied to interpret and translate the evidence into recommendation statements.
RECOMMENDATIONS: This Clinical Practice Guideline includes updated recommendations on who should receive osteoporosis pharmacotherapy, the benefits and risks of available pharmacotherapy options, treatment monitoring and follow-up, and the role of calcium and vitamin D in the management of postmenopausal osteoporosis. Recommendations are classified by strength and evidence quality. Ungraded Good Practice Points are included to provide guidance when a formal recommendation could not be made because of inadequate or nonexistent evidence.
| Errataetall: |
ErratumIn: Obstet Gynecol. 2022 Jul 1;140(1):138. - PMID 35849473 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:139 |
|---|---|
| Enthalten in: |
Obstetrics and gynecology - 139(2022), 4 vom: 01. Apr., Seite 698-717 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
ACOG Committee on Clinical Practice Guidelines–Gynecology [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 24.05.2022 Date Revised 16.11.2023 published: Print ErratumIn: Obstet Gynecol. 2022 Jul 1;140(1):138. - PMID 35849473 Citation Status MEDLINE |
|---|
| doi: |
10.1097/AOG.0000000000004730 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM34116741X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM34116741X | ||
| 003 | DE-627 | ||
| 005 | 20231226011144.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/AOG.0000000000004730 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1137.xml |
| 035 | |a (DE-627)NLM34116741X | ||
| 035 | |a (NLM)35594133 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a ACOG Committee on Clinical Practice Guidelines–Gynecology |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Management of Postmenopausal Osteoporosis |b ACOG Clinical Practice Guideline No. 2 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.05.2022 | ||
| 500 | |a Date Revised 16.11.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a ErratumIn: Obstet Gynecol. 2022 Jul 1;140(1):138. - PMID 35849473 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 by the American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved. | ||
| 520 | |a PURPOSE: To provide updated evidence-based recommendations for the treatment of postmenopausal osteoporosis | ||
| 520 | |a TARGET POPULATION: Postmenopausal patients with primary osteoporosis | ||
| 520 | |a METHODS: This guideline was developed using an a priori protocol in conjunction with a writing team consisting of two specialists in obstetrics and gynecology appointed by the ACOG Committee on Clinical Practice Guidelines-Gynecology and one external subject matter expert. ACOG medical librarians completed a comprehensive literature search for primary literature within Cochrane Library, Cochrane Collaboration Registry of Controlled Trials, EMBASE, PubMed, and MEDLINE. Studies that moved forward to the full-text screening stage were assessed by two authors from the writing team based on standardized inclusion and exclusion criteria. Included studies underwent quality assessment, and a modified GRADE (Grading of Recommendations Assessment, Development, and Evaluation) evidence-to-decision framework was applied to interpret and translate the evidence into recommendation statements | ||
| 520 | |a RECOMMENDATIONS: This Clinical Practice Guideline includes updated recommendations on who should receive osteoporosis pharmacotherapy, the benefits and risks of available pharmacotherapy options, treatment monitoring and follow-up, and the role of calcium and vitamin D in the management of postmenopausal osteoporosis. Recommendations are classified by strength and evidence quality. Ungraded Good Practice Points are included to provide guidance when a formal recommendation could not be made because of inadequate or nonexistent evidence | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Practice Guideline | |
| 650 | 7 | |a Calcium, Dietary |2 NLM | |
| 700 | 1 | |a Pinkerton, JoAnn V |e investigator |4 oth | |
| 700 | 1 | |a Chelmow, David |e investigator |4 oth | |
| 700 | 1 | |a Witkop, Catherine T |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Obstetrics and gynecology |d 1953 |g 139(2022), 4 vom: 01. Apr., Seite 698-717 |w (DE-627)NLM000021555 |x 1873-233X |7 nnns |
| 773 | 1 | 8 | |g volume:139 |g year:2022 |g number:4 |g day:01 |g month:04 |g pages:698-717 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/AOG.0000000000004730 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 139 |j 2022 |e 4 |b 01 |c 04 |h 698-717 | ||